Abbvie () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools for ...

Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...

The government website is meant to connect Americans with drug companies to buy prescriptions directly with their own money.

Feb 5 () - CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for ​lower-cost ...

CVS Health®   today announced new steps to further help customers expand adoption of lower-cost biosimilar medications. Effective April 1, 2026, CVS Caremark will begin offering osteoporosis ...

AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...

AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...

AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.

Despite AbbVie exceeding expectations for the last year and its forecast for 2026, its stock still fell in trading this morning as investors zeroed in on vulnerabilities in its tentpole drugs.

Turmeric and ibuprofen both reduce inflammation and pain, but they work in different ways. Learn how curcumin extract (from ...

Looking ahead, AbbVie's full-year 2026 adjusted earnings guidance is $14.37-$14.57 per share, above the analyst consensus of ...

The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...